Rivaroxaban for 18 Months Superior to 6 Months To Prevent Recurrent VTE Events in Cancer Patients with Acute-low PE: ONCO PE
Key Takeaways: The ONCO PE trial demonstrated that an 18-month treatment with rivaroxaban significantly reduced recurrent venous thromboembolism (VTE) compared to... Read more.
Semaglutide Improves CV Outcomes in Patients with Prior Coronary Artery Bypass Surgery: Insights from the SELECT Trial
Key Takeaways: In this secondary analysis of the SELECT Trial, semaglutide 2.4 mg once weekly significantly reduced the risk of major adverse cardiovascular events... Read more.
LAA Closure Associated With Less Bleeds vs. Oral Anticoagulation Post AF Ablation: OPTION
Key Takeaways: The OPTION TRIAL assessed the safety and efficacy of WATCHMAN FLX in a post-ablation contemporary clinical AF patient population at risk of stroke.... Read more.
Catheter Ablation Better Than Antiarrhythmic Drugs for VT in Ischemic Cardiomyopathy With ICD: VANISH2 Trial
Key Takeaways: The VANISH2 trial compared catheter ablation with systematic antiarrhythmic drug therapy as a first-line treatment strategy in patients with an ICD... Read more.
CLEAR SYNERGY: No Benefit with Routine Spironolactone in MI Patients
Key Takeaways: The CLEAR SYNERGY trial was a multicenter trial with a 2-by-2 factorial design which randomly assigned patients with myocardial infarction who had... Read more.
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran Associated with Durable Reductions in Serum TTR levels for ATTR -CM
Key Takeaways: A single dose of nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based therapy, achieved a 90% reduction in serum transthyretin (TTR) levels at 12 months... Read more.